Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) Net Income towards Common Stockholders: 2023-2025

Historic Net Income towards Common Stockholders for CG Oncology (CGON) over the last 3 years, with Sep 2025 value amounting to -$43.7 million.

  • CG Oncology's Net Income towards Common Stockholders fell 114.20% to -$43.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$151.4 million, marking a year-over-year decrease of 92.29%. This contributed to the annual value of -$88.0 million for FY2024, which is 29.85% down from last year.
  • Per CG Oncology's latest filing, its Net Income towards Common Stockholders stood at -$43.7 million for Q3 2025, which was down 5.52% from -$41.4 million recorded in Q2 2025.
  • CG Oncology's Net Income towards Common Stockholders' 5-year high stood at -$12.4 million during Q1 2023, with a 5-year trough of -$43.7 million in Q3 2025.
  • Over the past 3 years, CG Oncology's median Net Income towards Common Stockholders value was -$20.4 million (recorded in 2024), while the average stood at -$25.0 million.
  • Data for CG Oncology's Net Income towards Common Stockholders shows a maximum YoY plummeted of 119.14% (in 2025) over the last 5 years.
  • Over the past 3 years, CG Oncology's Net Income towards Common Stockholders (Quarterly) stood at -$22.5 million in 2023, then plummeted by 41.39% to -$31.8 million in 2024, then slumped by 114.20% to -$43.7 million in 2025.
  • Its last three reported values are -$43.7 million in Q3 2025, -$41.4 million for Q2 2025, and -$34.5 million during Q1 2025.